MARKET

INVA

INVA

Innoviva
NASDAQ
15.48
0.00
0.00%
After Hours: 15.46 -0.02 -0.13% 16:06 02/23 EST
OPEN
15.57
PREV CLOSE
15.48
HIGH
15.64
LOW
15.35
VOLUME
759.28K
TURNOVER
0
52 WEEK HIGH
16.87
52 WEEK LOW
10.64
MARKET CAP
992.06M
P/E (TTM)
28.78
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at INVA last week (0212-0216)?
Weekly Report · 6d ago
Dominate the Market With 3 Biotech Stocks
Investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), Foghorn Therapeutics (FHTX), and Vertex Pharmaceuticals (VRTX) The biotech industry’s growth prospects look promising due to the use of advanced technologies in drug development. The growing popularity of personalized medicine, an aging population, and expanding healthcare needs are boosting the long-term growth prospects of the biotech industry. Innoviva, Inc. Uses advanced technologies to develop targeted treatments for various diseases.
Barchart · 02/16 08:56
Weekly Report: what happened at INVA last week (0205-0209)?
Weekly Report · 02/12 09:13
Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly
Innoviva, Inc. Has US$445.7m of debt on its balance sheet. The company's EBIT fell 58% in the last 12 months. Debt is a tool to help a company grow, but it can also be a problem for a company. We look at debt levels to see if the debt is making the company risky. Innoviva has a moderate net debt to EBITDA ratio of 1.9. This suggests the company is managing its debt well. However, the company has 5 warning signs it has a high debt burden.
Simply Wall St · 02/05 10:15
Weekly Report: what happened at INVA last week (0129-0202)?
Weekly Report · 02/05 09:14
Weekly Report: what happened at INVA last week (0122-0126)?
Weekly Report · 01/29 09:13
Innoviva: Statement of changes in beneficial ownership of securities
Press release · 01/23 04:05
Innoviva: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 01/22 20:05
More
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).

Webull offers Innoviva Inc stock information, including NASDAQ: INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.